Our group focuses on systems-immunology-based approaches within the framework of Phase I to III clinical trials. We aim to identify surrogates of protection as well as host factors elicited by subunit and whole parasite vaccines against tuberculosis (TB) and malaria. Clinical trials are performed with our partners of the Ifakara Health Institute in Bagamoyo. Further, the unit develops novel diagnostic tools for paediatric clinical TB in high endemic countries.
Co-morbidity studies analyse the impact of non-communicable diseases on immune responses against infectious diseases, particularly TB. Unit researchers also work to understand the consequences of helminth co-infections on malaria, TB and HIV pathogenesis and immunity.
Latest PublicationsAll Publications
Caduff L et al. Inferring transmission fitness advantage of SARS-CoV-2 variants of concern from wastewater samples using digital PCR, Switzerland, December 2020 through March 2021. Euro Surveill. 2022;27(10). DOI: 10.2807/1560-7917.ES.2022.27.10.2100806
Daubenberger C, Burrows J.N. Volunteer infection studies accelerate the clinical development of novel drugs against malaria. Lancet Infect Dis. 2022;22:753-754. DOI: 10.1016/S1473-3099(21)00679-4
Daubenberger C. Assessment of experimental malaria vaccine induced protection in pre-exposed populations. Lancet Infect Dis. 2022;22(3):305-307. DOI: 10.1016/S1473-3099(21)00359-5
Daubenberger C.A, Gupta R. Monoclonal antibodies for reducing malaria transmission. Lancet Infect Dis. 2022(in press). DOI: 10.1016/S1473-3099(22)00413-3
Daubenberger C.A, Moncunill G. Next-generation malaria subunit vaccines to reduce disease burden in African children. Lancet Infect Dis. 2022(in press). DOI: 10.1016/S1473-3099(22)00523-0